This article will explore Ethylmorphine in detail, addressing its many facets and possible implications. Ethylmorphine is a topic of great relevance today, which has captured the attention of academics, experts and the general public. Through an exhaustive analysis, the different perspectives and approaches related to Ethylmorphine will be examined, with the aim of providing a complete and enriching vision on this topic. From its origins to its impact on contemporary society, this article will seek to shed light on Ethylmorphine and encourage informed and thoughtful debate.
![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Cosylan, Diolan, Dionina, Diosan, Solvipect, Trachyl |
AHFS/Drugs.com | International Drug Names |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.883 |
Chemical and physical data | |
Formula | C19H23NO3 |
Molar mass | 313.397 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Ethylmorphine (also known as codethyline, dionine, and ethyl morphine) is an opioid analgesic and antitussive.[2][3][4][5][6][7]
Adverse effects are similar to other opioids and include drowsiness, constipation, vertigo, nausea, vomiting, and respiratory depression. Contraindications include asthma, respiratory insufficiency, and age under 8. Ethylmorphine may affect the user's ability to drive and operate heavy machinery, and may cause chemical dependence or addiction at high doses.[8]
Ethylmorphine was first marketed in France in 1953 by Houde, and in Norway and Spain in 1960. It is not available in the United States, where it is a Schedule II controlled substance.[8][9]